BC43 Inter-amer 30

RNS Number:3564S
Lilly (Eli) & Co
4 March 2002

Lilly Provides Interim Update of Early 2002 Xigris Sales

Eli Lilly and Company (NYSE: LLY) today announced the year-to-date 2002 sales of
Xigris(TM) ((drotrecogin alfa (activated)), Lilly's breakthrough treatment for
adult severe sepsis patients at high risk of death. Lilly is providing an
interim update of early 2002 sales due to the lack of complete third party
reporting of Xigris sales information. For the year-to-date period ending
February 28,2002, Xigris sales were approximately $14 million, bringing the
cumulative sales since its late-November 2001 launch to about $35 million.
Hospital stocking in December 2001 partially affected early 2002 sales results.

"Some challenges have affected the initial uptake of Xigris," said Charles E.
Golden, executive vice president and chief financial officer for Lilly. "These
have included the time needed by some of the larger institutions to develop
treatment protocols and place the product on their formularies. In addition, the
selection of patients with severe sepsis as indicated in the label has been
complex for physicians initially. However, for hospitals that have used Xigris,
reorder rates have been robust because, once physicians use Xigris, they tend to
use it again. We are also pleased with the growth in the number of patients who
are receiving this innovative new therapy for their life-threatening severe
sepsis. With these encouraging patient-start and hospital-buying trends and our
significant efforts to educate health care professionals about this first-in-
class product, we anticipate a steady increase in sales during 2002. We believe
Xigris will become a great commercial success," he said.

The company reiterated its 2002 earnings-per-share guidance of $2.70 to $2.80,
excluding unusual items, and its 2002 sales growth expectations of low-to-mid
single digits. The company also continues to target high-teens earnings-per-
share growth for 2003.

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of best-in-class pharmaceutical products by applying the latest
research from its own worldwide laboratories and from collaborations with
eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly
provides answers - through medicines and information - for some of the world's
most urgent medical needs. Additional information about Lilly is available at
www.lilly.com.

These forward-looking statements are based on management's current expectations
but actual results may differ materially due to various factors. As with any
truly novel pharmaceutical product, it is difficult to predict the growth rate
for Xigris sales because of the lack of any industry precedent. Also, there are
significant risks and uncertainties in pharmaceutical research and development.
There can be no guarantees with respect to pipeline products that the products
will receive the necessary clinical and manufacturing regulatory approvals or
that they will prove to be commercially successful. The company's results may
also be affected by such factors as the continuing impact of generic fluoxetine
on Prozac sales in the United States, competitive developments affecting current
growth products, the timing of anticipated regulatory approvals and launches of
new products, other regulatory developments involving current and future
products, the impact of governmental actions regarding coverage and
reimbursement for pharmaceuticals, and the impact of exchange rates. For
additional information about the factors that affect the company's business,
please see Exhibit 99 to the company's latest Form 10-Q filed November 2001. The
company undertakes no duty to update forward-looking statements.              

Xigris(TM) (drotrecogin alfa (activated), Lilly)




                      This information is provided by RNS
            The company news service from the London Stock Exchange

Inter-amer 30 (LSE:BC43)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Inter-amer 30 (LSE:BC43)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025